Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma

dc.contributor.author	Uriol Egido, Esther
dc.contributor.author	Galván Hernández, José Alberto
dc.contributor.author	Álvarez, Celso
dc.contributor.author	Pérez, Q.
dc.contributor.author	Villanueva Palicio, Noemí
dc.contributor.author	Berros Fombella, José Pablo
dc.contributor.author	Izquierdo, María
dc.contributor.author	Viéitez de Prado, José María
dc.date.accessioned	2013-11-27T11:30:20Z
dc.date.available	2013-11-27T11:30:20Z
dc.date.issued	2013
dc.identifier.citation	Case Reports in Oncology, 6(2), p. 441-449 (2013); doi:10.1159/000354754
dc.identifier.issn	1662-6575
dc.identifier.uri	http://hdl.handle.net/10651/19967
dc.description.sponsorship	Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals.
dc.format.extent	p. 441-449
dc.language.iso	eng
dc.relation.ispartof	Case Reports in Oncology
dc.rights	© 2013 S. Karger AG, Base
dc.rights	Reconocimiento - No comercial - Sin obras derivadas 4.0 Internacional
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	SCOPUS
dc.title	Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma
dc.type	journal article
dc.identifier.local	20131179
dc.identifier.doi	10.1159/000354754
dc.relation.publisherversion	http://dx.doi.org/10.1159/000354754
dc.rights.accessRights	open access

Este ítem está sujeto a una licencia Creative Commons